Compare Cassava Sciences Inc (FLNA) vs Ubs Ag Etracs Crude Oil Shares Covered Call ETN Exp 24th Apr 2037 (USOI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs Ubs Ag Etracs Crude Oil Shares Covered Call ETN Exp 24th Apr 2037 — how do they compare? Cassava Sciences Inc trades at $0.82 (market cap $39.40M), while Ubs Ag Etracs Crude Oil Shares Covered Call ETN Exp 24th Apr 2037 trades at $45.28 (market cap $311.72M). The key difference: Ubs Ag Etracs Crude Oil Shares Covered Call ETN Exp 24th Apr 2037 is far larger — about 7.9× Cassava Sciences Inc's market cap, and Ubs Ag Etracs Crude Oil Shares Covered Call ETN Exp 24th Apr 2037 is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Cassava Sciences Inc for 37 Days and Ubs Ag Etracs Crude Oil Shares Covered Call ETN Exp 24th Apr 2037 for 48 Days on average.
| FLNA | USOI | |
|---|---|---|
Market Cap | $39.40M | $311.72M |
Volume | 759,018 | 75,888 |
Sector | Health | Income / Options Overlay |
52-Week High | $4.64 | $61.17 |
52-Week Low | $0.68 | $42.27 |
Typical Hold Time | 37 Days | 48 Days |
Enterprise Value | -$43.28M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $0.8157, down 6.77% today, with a bearish technical signal from moving averages. The company shows improving quarterly EPS trends, beating expectations in recent quarters, though it remains unprofitable with negative ROE and ROA. Recent FDA clearance for its epilepsy drug trial provides a positive catalyst. Analyst sentiment is bullish with 67% buy ratings.
The outlook hinges on clinical progress; upside exists if Phase 2a trials succeed, but high cash burn and lack of revenue pose significant risks. Investors should weigh the strong analyst support against the company's financial challenges and binary clinical outcomes.
USOI trades at $44.61, down 0.82% today, with a bearish technical signal driven by moving averages. Support levels are at $44 and $43, while resistance sits at $45 and $46. Financial ratios like P/E and P/S are unavailable in the data, limiting fundamental clarity. Recent portfolio commentary from Seeking Alpha on September 3, 2026, highlighted strategic cash-raising moves, though direct company news is sparse.
The outlook is cautious due to weak technical momentum and absent fundamental metrics. Risks include market volatility and lack of earnings visibility. Investment opportunity hinges on a rebound above resistance, but current sentiment and technicals suggest near-term pressure for stockholders.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About Ubs Ag Etracs Crude Oil Shares Covered Call ETN Exp 24th Apr 2037
USOI is an Exchange-Traded Note (ETN) issued by UBS that provides exposure to a covered call strategy on the United States Oil Fund (USO). It aims to generate high monthly income by capturing option premiums from the hypothetical sale of out-of-the-money call options on oil shares, offering a way to profit from crude oil's volatility even in a flat or range-bound market.
Read more on USOI →
